CVRdatabase
Menu

Scanpharm A/S

Public limited companyCVR 16279099BirkerødActive

Scanpharm A/S is a public limited company, based in Birkerød, active in manufacture of pharmaceutical preparations, founded in 1992. Net profit rose 65% from 2024 to 2025, ending at DKK 963k. With 40 employees, the company is about 4 times larger than the industry median. Equity grew to DKK 3m in 2025.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profitDKK 29.7m+10.5% vs. 2024
Net profitDKK 963k+65.2% vs. 2024
EquityDKK 3m+46.2% vs. 2024
Employees40latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • Gross profit rose 10% (2024 → 2025), to DKK 29.7m.
  • Net profit rose 65% (2024 → 2025), to DKK 963k.
  • Equity rose 46% (2024 → 2025), to DKK 3m.

Management and owners, last 24 months

  • New in management: Andreas Bjørn Jensen (board member, 25/02/2026).
  • Stepped down: Ole Bjørn Jensen (board member, 25/02/2026).

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 20m−DKK 15m−DKK 10m−DKK 5mDKK 0DKK 5m202020212022202320242025
EquityNet profit
Financial figures for Scanpharm A/S
202020212022202320242025Change
Revenuenot statednot statednot statednot statednot statednot stated–
Gross profit5,11811,25917,39922,51926,90429,717+10.5%
Operating profit (EBIT)−16,096−9,718−5,205−3,5331,6791,721+2.5%
Profit before tax−17,099−10,785−6,106−4,425583963+65.2%
Net profit−18,941−10,871−5,954−4,425583963+65.2%
Total assets32,22428,91129,65931,60235,06839,207+11.8%
Equity1,9131,5001,5001,5002,0833,045+46.2%
Liabilities30,31127,41128,15930,10232,98636,162+9.6%
Average number of employees40404144420−100%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

DKK 0DKK 5mDKK 10mDKK 15mDKK 20mDKK 25mDKK 30m202020212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Low equity ratio

    Equity makes up 8% of total assets in 2025.

    How is this calculated?

    Equity ÷ total assets is below 10% in the latest annual report. Banks, insurers and some industries naturally have a low ratio.

  • Fewer employees

    The number of employees fell 100% from 42 in 2024 to 0 in 2025.

    How is this calculated?

    The number of employees according to the annual report has fallen by at least 25%, and was at least 10 the year before.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Scanpharm A/S
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202515/06/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202420/05/2025The companyPDFXBRL
202301/01/2023 – 31/12/202302/07/2024The companyPDFXBRL
202201/01/2022 – 31/12/202203/07/2023The companyPDFXBRL
202101/01/2021 – 31/12/202105/07/2022The companyPDFXBRL
202001/01/2020 – 31/12/202009/07/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
010203040506009/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/2608/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profitDKK 29.7mNo. 18 of 57
Better than 70% of the companies in the industry
EquityDKK 3mNo. 36 of 59
Better than 40% of the companies in the industry
Number of employees40No. 52 of 59
Better than 12% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bnHere
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 20–49 employees9,922 companies in the comparison
No. 1,381of 9,892
Better than 86%
No. 5,753of 9,922
Better than 42%
Companies that are at least 30 years old10,276 companies in the comparison
No. 2,158of 10,152
Better than 79%
No. 7,161of 10,275
Better than 30%
All companies of type A/S18,025 companies in the comparison
No. 4,442of 17,786
Better than 75%
No. 13,278of 18,024
Better than 26%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. Scanpharm A/SDKK 29.7m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. Scanpharm A/SDKK 963k
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. Scanpharm A/SDKK 3m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. Scanpharm A/S40
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Peluli Holding ApS10%
  • Chlopethan A/S90%
Scanpharm A/S

Management

4 active registrations

Executive management

Executive management at Scanpharm A/S
NameRoleAppointed
Andreas Bjørn JensenCEO28/02/2019

Board of directors

Board of directors at Scanpharm A/S
NameRoleAppointed
Hanne Bjørn JensenBoard member01/07/1992
Janus Doré PaghChair of the board06/01/2022
Andreas Bjørn JensenBoard member25/02/2026
Auditor
Bent Lind Kofoed
Founders
VX 10.312 ApS, Medimex ApS, ApS Kbil 9 Nr. 1008
Former management (10)
Former management at Scanpharm A/S
NameRoleAppointedResigned
Ole Bjørn JensenBoard member01/07/199225/02/2026
Ole Bjørn JensenDirector01/07/199230/01/2018
Hans Christian GalstBoard member01/07/199205/01/1993
Kim Aage EgegaardBoard member01/07/199231/05/1999
Ulf Svejgaard PoulsenChair of the board01/07/199205/01/1993
Per Emil Hasselbalch StakemannBoard member01/07/199205/01/1993
Per Emil Hasselbalch StakemannDirector01/07/199205/01/1993
Jens Terkel Lund-NielsenBoard member31/05/199914/10/2010
Holger Carsten HansenChair of the board14/10/201006/01/2022
Rolf EckersbergDirector30/01/201828/02/2019

Signing rule: Selskabet tegnes af bestyrelsens formand og en direktør i forening eller af den samlede bestyrelse.

Address and production units

1 active production units

Topstykket 12
3460 Birkerød

Rudersdal Municipality · Postcode 3460

Production units
Production unitAddressEmployeesP number
SCANPHARM A/STopstykket 12, 3460 Birkerød401001071414

Purpose

Selskabets formål er at drive handel og produktion

The purpose is quoted from the register in Danish.

Changes year by year

47 registered events
20263 changesaccounts 1 · management 2
  • Annual report for 2025 published
  • Andreas Bjørn Jensen appointed board member
  • Ole Bjørn Jensen stepped down as board member
20251 changeaccounts 1
  • Annual report for 2024 published
20241 changeaccounts 1
  • Annual report for 2023 published
20231 changeaccounts 1
  • Annual report for 2022 published
20223 changesaccounts 1 · management 2
  • Annual report for 2021 published
  • Janus Doré Pagh appointed chair of the board
  • Holger Carsten Hansen stepped down as chair of the board
20211 changeaccounts 1
  • Annual report for 2020 published
20195 changesownership 3 · management 2
  • CHLOPETHAN A/S registered as owner (90%)
  • E CONSULT ApS is no longer registered as owner
  • Andreas Bjørn Jensen appointed ceo
  • Rolf Eckersberg stepped down as director
  • CHLOPETHAN A/S is no longer registered as owner
20186 changesmanagement 2 · ownership 4
  • Rolf Eckersberg appointed director
  • Ole Bjørn Jensen stepped down as director
  • E CONSULT ApS registered as owner (10%)
  • CHLOPETHAN A/S registered as owner (66.67%)
  • CHLOPETHAN A/S is no longer registered as owner
  • Peluli Holding ApS registered as owner (10%)
20112 changescapital 1 · ownership 1
  • Share capital changed from 2,000,000 DKK to 3,000,000 DKK
  • CHLOPETHAN A/S registered as owner (100%)
20102 changesmanagement 2
  • Holger Carsten Hansen appointed chair of the board
  • Jens Terkel Lund-Nielsen stepped down as board member
20081 changeindustry 1
  • Industry changed to Manufacture of pharmaceutical preparations (212000)
20071 changeaddress 1
  • Moved to Topstykket 12, 3460 Birkerød
20021 changemerger 1
  • Merger registered in CVR
19992 changesmanagement 2
  • Jens Terkel Lund-Nielsen appointed board member
  • Kim Aage Egegaard stepped down as board member
19951 changename 1
  • Name changed from SCANPHARM A/S AF 1992 to SCANPHARM A/S
19937 changesname 2 · capital 1 · management 4
  • Name changed from A/S SCANPHARM AF 1992 to SCANPHARM A/S AF 1992
  • Name changed from A/S PSE NR. 4681 to A/S SCANPHARM AF 1992
  • Share capital changed from 500,000 DKK to 2,000,000 DKK
  • Per Emil Hasselbalch Stakemann stepped down as director
  • Per Emil Hasselbalch Stakemann stepped down as board member
  • Ulf Svejgaard Poulsen stepped down as chair of the board
  • Hans Christian Galst stepped down as board member
19929 changesfounded 1 · management 8
  • Registered as A/S PSE NR. 4681
  • Per Emil Hasselbalch Stakemann appointed director
  • Ole Bjørn Jensen appointed board member
  • Per Emil Hasselbalch Stakemann appointed board member
  • Ulf Svejgaard Poulsen appointed chair of the board
  • Hanne Bjørn Jensen appointed board member
  • Kim Aage Egegaard appointed board member
  • Hans Christian Galst appointed board member
  • Ole Bjørn Jensen appointed director

Related companies

Same industry in Rudersdal

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.

View in CVRReport a correction